Inventor · disambiguated record
Yong Li
Also filed as: LI YONG · Li yong-xin
7 granted patents·20 pending applications·7 citations·filing 2011–2024
77Inventor score
Top patents by PatentIndex Score
27 records- 0189US11161850B2Fused pyrazine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2019·Granted Nov 2, 2021·5 cites·12 claims
- 0276US2025041310A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 0375US2024360140A1Fused pyrazine derivatives as a2a / a2b inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 0475US2025059293A1Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2024·Application pending·0 cites
- 0569US2025188073A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2024·Application pending·0 cites
- 0668US8741955B2D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disordersFOSTER ALAN C·Filed 2012·Granted Jun 3, 2014·1 cites·3 claims
- 0768US8735451B2D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disordersFOSTER ALAN C·Filed 2012·Granted May 27, 2014·1 cites·9 claims
- 0867US11999740B2Fused pyrazine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2021·Granted Jun 4, 2024·0 cites·36 claims
- 0967US2025084063A1Bicyclic heterocycles as mrgprx2 antagonistsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1064US2025270217A1Imidaz0[1,2-a]pyrimidine-5(1 h)-ones having a covalent warhead at the 3-position as wrn inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1163US9415031B2D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disordersALLERGAN INC·Filed 2014·Granted Aug 16, 2016·0 cites·20 claims
- 1263US2025084087A1Bicyclic heterocycles as mrgprx2 antagonistsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1362US12060433B2CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2020·Granted Aug 13, 2024·0 cites·39 claims
- 1461US2021205311A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 1560US2014200254A1D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disordersALLERGAN INC·Filed 2014·Application pending·0 cites
- 1658US2022233529A1Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodiesINCYTE CORP·Filed 2021·Application pending·0 cites
- 1758US2021269434A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2021·Application pending·0 cites
- 1857US2023226040A1Combination therapy comprising an fgfr inhibitor and a kras inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 1956US12441727B2Tricyclic compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Oct 14, 2025·0 cites·31 claims
- 2055US2017172957A1D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disordersALLERGAN INC·Filed 2016·Application pending·0 cites
- 2153US2012329873A1D-serine for the treatment of visual system disordersLi yong-xin·Filed 2012·Application pending·0 cites
- 2252US2015174095A1Pharmaceutical compositions for the treatment of visual system disordersALLERGAN INC·Filed 2014·Application pending·0 cites
- 2351US2017172959A1D-serine for the treatment of visual system disordersALLERGAN INC·Filed 2016·Application pending·0 cites
- 2449US2022332726A1Nitroxide derivative of rock kinase inhibitorVIVAVISION SHANGHAI LTD·Filed 2020·Application pending·0 cites
- 2545US2024254156A1Novel isoflavone compoundNABOCUL COSMETICS CO LTD·Filed 2022·Application pending·0 cites
- 2644US2020171026A1Prostacyclin receptor agonists for reduction of body fatALLERGAN INC·Filed 2018·Application pending·0 cites
- 2739US2011257186A1Compositions and methods for treating visual disordersSTAUBLI URSULA V·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yong Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →